Articles by Amy Ritter - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Amy Ritter

Foreign Scientists Welcome, Sort Of

Jul 28, 2011

The age of globalized industry should result in fewer barriers between countries, but in practice it is rarely that straightforward, according to a report by ScienceInsider.

Bipartisan Bill Introduced to Encourage Generic Drug Use in Medicaid

Jul 21, 2011

A bill introduced by Senators Scott Brown (R-MA), Ron Wyden (D-OR), and John McCain (R-AZ) on July 13, 2011, aims to encourage states to reduce Medicaid spending by offering financial incentives to substitute generic drugs for branded ones where possible.

The Economic Contribution of the US Biopharmaceutical Industry

Jul 14, 2011

Recent trends in the US biopharmaceutical industry suggest this is a pivotal area for potential job creation.

House Committee Expands Investigation into Tainted Heparin

Jul 7, 2011

Members of the House Energy and Commerce Committee are expanding their investigation into the 2008 entry of contaminated heparin from China into the United States market.

FDA Q11 Draft Guidance Available for Comment

Jul 7, 2011

FDA issued a draft guidance, entitled "Q11 Development and Manufacture of Drug Substances," which is now available for comment according to a notice published on June 29, 2011, in the Federal Register.

J&J Issues Voluntary Recall of Risperdal

Jun 23, 2011

A subsidiary of Johnson & Johnson initiated a voluntary recall of its antipsychotic medication, Risperdal, due to an unusual odor.

FDA Issues Draft Guidance on Nanotechnology

Jun 16, 2011

An FDA guidance has provided information for products that involve the application of nanotechnology, and rationales for those points.

J&J Ordered to Pay $327 Million Penalty in False-Claim Suit

Jun 9, 2011

A South Carolina court found that a subsidiary of Johnson & Johnson violated state consumer protection laws by using misleading marketing for its antipsychotic drug, Risperdal.

Mylan Plans Direct Entry Into Indian Market

Jun 2, 2011

Mylan, a generic-drug manufacturer, announced that it will be rebranding its Hyderabad, India-based subsidiary, Matrix Laboratories, as Mylan.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here